Market atlas / Sirtuin activators (STAC) / Pterostilbene
Pterostilbene (sirtuin activator, STAC)
traditional-to-validatedsmall-moleculesirtuin-activationpolyphenol● sirt1
Stage by geography
signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUS
MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS
What each market approved it for
| Market | Stage | Since | Indication / class / form |
|---|---|---|---|
| US | consumer | not dated | not published |
Biomarker trends
no biomarker readings yet
Studies
The studies on Pterostilbene, what they found, in whom and how strongly, are on its evidence page, each linked to its source.
What the trials measure
Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.
| Registered primary endpoint | Markets measuring it |
|---|---|
| LDL | US |
| Complications | US |
| Tumor Ki-67 Proliferation Index | US |
| Production of Estradiol | US |
| Change undesirable effects of menopause | US |
| Preliminary Efficacy: Cytopenia Improvement | US |
| AKI | US |
Connections
Trajectory
2026
MarketUS: consumer (US dietary supplement (DSHEA), not FDA-approved as a drug)
DSLD:18482 · machine-extracted
Get into the weeds: raw observations + provenance
pter_edge_resv 2026-06-29 kind=edge verify=M both stilbene sirtuin-activator polyphenols source NCT03671811 https://clinicaltrials.gov/study/NCT03671811 pter_facets 2026-06-29 kind=facets verify=M Pterostilbene facets source NCT03671811 https://clinicaltrials.gov/study/NCT03671811 pter_us_trial 2026-06-29 kind=geography_stage verify=M Pterostilbene: US phase 2 trials [NCT03671811] source NCT03671811 https://clinicaltrials.gov/study/NCT03671811 pter_us_consumer 2026-06-29 kind=geography_stage verify=M Pterostilbene sold as a US dietary supplement source DSLD:18482 https://dsld.od.nih.gov/label/18482